Table 1.

Observed and predicted ∆QTcF and pharmacokinetic parameter values on day 3 following daily oral administration of CQ or CQ + AZ to healthy subjects

Group	Vs. Placebo		Vs. CQ		CQ		AZ		Predicted maximum ∆QTcF effect due to AZ, msec
	Maximum ∆QTcF, msec	Time of maximum ∆QTcF, hours	Maximum ∆QTcF, msec	Time of maximum ∆QTcF, hours	Cmax, µg/mL	Tmax, hours	Cmax, µg/mL	Tmax, hours	Predicted effects at AZ Cmax using p.o. studya	Predicted effects at AZ Cmax using i.v. studyb
	(90% CI)		(90% CI)		(%CV)	(%CV)	(%CV)	(%CV)
CQ	35.0	10	–	–	0.314	7.65	–	–	–	–
	(29.9–40.2)				(28)	(39)
CQ + 500 mg AZ	36.2	10	5.31	2	0.356	6.44	0.53	1.44	3.78	0.72
	(31.0–41.6)		(0.19–10.4)		(35)	(47)	(33)	(38)
CQ + 1000 mg AZ	36.9	10	6.51	1	0.336	6.20	0.957	1.32	6.83	1.30
	(31.7–42.0)		(1.38–11.6)		(27)	(58)	(31)	(29)
CQ + 1500 mg AZ	35.0	6	8.88	2	0.334	6.27	1.54	1.35	11.00	2.09
	(29.7–40.4)		(3.56–14.2)		(22)	(68)	(28)	(30)

∆QTcF, Fridericia corrected QT interval; AZ, azithromycin; CI, confidence interval; C_max, maximum plasma concentration; CQ, chloroquine; %CV, coefficient of variation in percent; T_max, time to maximum plasma concentration.

^aAzithromycin plus chloroquine p.o. study analysis.

^bAzithromycin i.v. study analysis.